Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | TYK2 | P29597 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 14/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | CCNK | O75909 | 2/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31378274 | 1.00 | JAK2 (0.51) | JAK2JAK1TYK2JAK3EGFR | |
| SCHEMBL22712691 | 1.00 | JAK2 (0.51) | JAK2JAK1TYK2JAK3EGFR | |
| SCHEMBL21275052 | 0.86 | CSNK2A2 (0.41) | JAK2JAK1TYK2JAK3EGFR | |
| SCHEMBL23165013 | 0.84 | EGFR (0.53) | JAK2JAK1TYK2JAK3EGFR | |
| SCHEMBL21275252 | 0.82 | EML4 (0.41) | EGFRBTKCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL21275247 | 0.82 | EML4 (0.41) | EGFRBTKCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL26103631 | 0.79 | EGFR (0.42) | JAK2JAK1TYK2JAK3EGFR | |
| SCHEMBL26103638 | 0.79 | EGFR (0.42) | JAK2JAK1TYK2JAK3EGFR | |
| SCHEMBL28684083 | 0.77 | BTK (0.43) | JAK2JAK1TYK2JAK3EGFR | |
| SCHEMBL23164305 | 0.77 | BTK (0.43) | JAK2JAK1TYK2JAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12086788-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230140433-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-11-17 | — | — | US | disclosed |
| US-11501284-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3930717-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021066958-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3755702-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | Newave Pharmaceutical Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200377478-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019161152-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11501284-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | BTK, SYK, LYN | JAK2 4/4885JAK1 9/4885TYK2 10/4885 |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | JAK2 4/4885JAK1 9/4885TYK2 10/4885 |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | JAK2 4/4885JAK1 8/4885TYK2 15/4885 |
| US-20230140433-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | JAK2 5/4885JAK1 10/4885TYK2 17/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | JAK2 74/4885JAK1 79/4885TYK2 40/4885 |
| US-12086788-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | BTK, SYK, LYN | JAK2 4/4885JAK1 9/4885TYK2 10/4885 |
| US-20200377478-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | JAK2 5/4885JAK1 10/4885TYK2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.